These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6839559)

  • 1. The effect of alterations of uremic retention products upon platelet and peripheral nerve function.
    Lindsay RM; Bolton CF; Clark WF; Linton AL
    Clin Nephrol; 1983 Mar; 19(3):110-5. PubMed ID: 6839559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia.
    Avram MM; Feinfeld DA; Huatuco AH
    N Engl J Med; 1978 May; 298(18):1000-3. PubMed ID: 205786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood levels of middle molecules and their effects on motor nerve conduction velocity.
    Botella J; Gea T; Sanz-Guajardo D; Criado M; Torres MT; Guardiola J
    Artif Organs; 1981; 4 Suppl():151-5. PubMed ID: 7295082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100 ): influence of hematocrit elevation.
    Escolar G; Cases A; Viñas M; Pino M; Calls J; Cirera I; Ordinas A
    Haematologica; 1999 Jul; 84(7):614-9. PubMed ID: 10406903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet function as an assay for uremic toxins.
    Lindsay RM; Dennis BN; Bergström JC; Jonsson C; Fürst P
    Artif Organs; 1981; 4 Suppl():82-9. PubMed ID: 7295101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adequacy of dialysis.
    Lindsay RM; Henderson LW
    Kidney Int Suppl; 1988 Mar; 24():S92-9. PubMed ID: 3283413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Middle molecular weight substances and uremic polyneuropathy.
    Dukanović L; Petrović J; Potić J
    Acta Med Iugosl; 1990; 44(2):117-28. PubMed ID: 2162129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "In vitro" inhibition of platelet aggregation by uremic middle molecules.
    Gallice P; Fournier N; Crevat A; Saingra S; Frayssinet R; Murisasco A; Sicardi F
    Biomedicine; 1980; 33(6):185-8. PubMed ID: 7213919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of polyneuropathy severity in chronic renal failure patients on continuous ambulatory peritoneal dialysis or on maintenance hemodialysis].
    Janda K; Stompór T; Gryz E; Szczudlik A; Drozdz M; Kraśniak A; Sułowicz W
    Przegl Lek; 2007; 64(6):423-30. PubMed ID: 18159852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa.
    Thekkedath UR; Chirananthavat T; Leypoldt JK; Cheung AK; Mohammad SF
    Am J Hematol; 2006 Dec; 81(12):915-26. PubMed ID: 16917914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Modification of uremic thrombocytopathy by hemodialysis].
    Frick U; Frick G; Vitu J; Wiedenhöft I
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(2):309-13. PubMed ID: 6194064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet function in patients on maintenance hemodialysis: depressed or enhanced?
    Remuzzi G; Benigni A; Dodesini P; Schieppati A; Gotti E; Livio M; Mecca G; Donati B; de Gaetano G
    Clin Nephrol; 1982 Feb; 17(2):60-3. PubMed ID: 7067167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
    Elshamaa MF; Elghoroury EA; Helmy A
    Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Examination of lymphokines in patients with hemodialysis (author's transl)].
    Löcsey L; Kálmán K; Hauck M; Kakuk G
    Allerg Immunol (Leipz); 1979; 25(3):211-7. PubMed ID: 162030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of platelet function by uremic middle molecules.
    Bazilinski N; Shaykh M; Dunea G; Mamdani B; Patel A; Czapek E; Ahmed S
    Nephron; 1985; 40(4):423-8. PubMed ID: 4022211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor and sensory nerve conduction in uremic patients undergoing repeated dialysis.
    Codish SD; Cress RH
    Arch Phys Med Rehabil; 1971 Jun; 52(6):260-3. PubMed ID: 5090268
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients.
    Brophy DF; Martin EJ; Carr SL; Kirschbaum B; Carr ME
    Thromb Res; 2007; 119(6):723-9. PubMed ID: 16793120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.